Open company graph database — free web & API
Login

HIROTSU BioScience Inc.

株式会社HIROTSUバイオサイエンス
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
31
§01

Basic information

BASIC
Head office
22nd Floor, New Okta Garden Court, 4-1 Kioi-cho, Chiyoda-ku, Tokyo 102-0094Sources
Chief executive
Takashi HirotsuSources
Capital
7,301,185,000 JPY (73 100 millionJPY)
Employees (non-consolidated)
Employees (consolidated)
Start date
2016-08-01
End date
§02

Websites

1 DOMAINS
§03

Business

1
Biological diagnostic research: research, development, and sales of cancer testing using nematode and nematode olfactory sensorsSources
§04

Related companies

31 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Hirotsu Global Inc. Sources
Group Subsidiary
米国法人HIROTSU&CO.,INC. Sources
Group Subsidiary
豪州法人HIROTSU BIO AUSTRALIA PTY. LTD. Sources
Group Subsidiary
HATARAKUエルダー株式会社 Sources
Alliance
Toppan Edge Inc. Sources
Alliance
あいおいニッセイ同和損害保険株式会社 Sources
Alliance
Hibishin Capital Corporation Sources
Alliance
みらかホールディングス株式会社 Sources
Alliance
Aswan Co., Ltd. SourcesSources
Alliance
Avex Healthcare Empower LLC Sources
Alliance
エイベックス株式会社 SourcesSources
Alliance
トッパン・フォームズ株式会社 Sources
Alliance
Future Venture Capital Co., Ltd. Sources
Alliance
Free Bank Capital Co., Ltd. Sources
Alliance
Mitsui Sumitomo Insurance Aioi Life Insurance Co., Ltd. Sources
Alliance
信金キャピタル株式会社 Sources
Alliance
MEIDEN HOKUTO CORPORATION Sources
Alliance
Sojitz Corporation Sources
Alliance
J Risk Management Co., Ltd. Sources
Alliance
Ichinen Holdings Co., Ltd. SourcesSources
Alliance
Nippon Broadcasting System, Inc. SourcesSources
Alliance
Holipro Inc. SourcesSources
Alliance
Kurume Research Park Co., Ltd. Sources
Alliance
Yoshinoya Holdings Co., Ltd. Sources
Alliance
株式会社東急エージェンシー Sources
Alliance
株式会社法研 Sources
Alliance
Rihonetsu Co., Ltd. Sources
Alliance
DENTSU INC. Sources
Alliance
Ikeda Seishu Holdings Co., Ltd. Sources
Alliance
Dai-ichi Life Sources
Alliance
西濃運輸&GENie Sources
Alliance
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

122 EVENTS

A paper by developer Hirotsu clarifying the involvement of the Ras-MAPK pathway in nematode olfactionSources

Published in the English scientific journal "Nature"Sources

Inoue Science Promotion FoundationSources

Developer Hirotsu received the "Inoue Research Encouragement Award"Sources

The first clinical research paper by developer Hirotsu on nematode olfaction detecting cancer odorsSources

Published in the online journal "PLOS ONE"Sources

This invention became the top news on TV Asahi's "Reporting Station"Sources

Reported by many other media, causing a great impact in various fieldsSources

Aiming to commercialize the nematode cancer test "N-NOSE"Sources

Established HIROTSU BioScience Inc. (Headquarters: Akasaka, Minato-ku, Tokyo)Sources

Institute of Science and Technology Policy, Ministry of Education, Culture, Sports, Science and TechnologySources

Selected as a representative for "Nice Step Researchers 2016"Sources

NeuroCreative Research Association (NPO)Sources

Representative received the "Development Research Encouragement Award"Sources

Science Promotion Foundation (Public Foundation)Sources

Representative received the "Nakayama Prize Encouragement Award"Sources

[Newly added joint clinical research site]Sources

Minami-Fu HospitalSources

Implemented a third-party allotment of capital (first round in 2017)Sources

Opened Central Research Institute, Fukuoka Research Institute, and Shikoku Analysis Center.Sources

Representative delivered an invited lecture at the Brisbane Cancer Conference 2017.Sources

Established Australian subsidiary HIROTSU BIO AUSTRALIA PTY. LTD.Sources

Implemented a third-party allotment of additional shares to multiple companies (second round in 2017).Sources

Ministry of Economy, Trade and Industry.Sources

Our company was selected as a 'Regional Future Leading Company'.Sources

[Newly added joint clinical research sites]Sources

Shikoku Cancer Center, Ageo Central General Hospital Gastroenterology Department, Hills Garden Clinic, Ebara Welfare Hospital, Saitama Medical University International Medical Center Gastroenterology Department, Toda Central General Hospital Gastroenterology Department, Inazawa Welfare Hospital Gastroenterology Department, Ibi Welfare Hospital, Queensland University of Technology, Shin-Yamate Hospital Gastrointestinal Surgery & Respiratory Medicine, Minami-Fu Hospital & Shionogi Pharmaceutical, Osaka University Gastroenterology Department, Kurume University Cancer Integrated Treatment Center.Sources

Moved headquarters to Minami-Aoyama, Minato-ku, Tokyo, due to business expansion.Sources

Implemented a third-party allotment of additional shares to multiple companies (first round in 2018).Sources

Fukuoka Prefecture.Sources

Our company was selected for the Fukuoka Prefecture Innovative Cancer Ultra Early Diagnosis Technology Implementation Project.Sources

Signed capital and business alliance agreements with Toppan Forms Co., Ltd., Azwan Co., Ltd., Ichinen Holdings Co., Ltd., Miraka Holdings Co., Ltd., Avex Co., Ltd., and Nippon Broadcasting Co., Ltd.Sources

Implemented a third-party allotment of additional shares (second round in 2018).Sources

Representative appointed as visiting associate professor at Queensland University of Technology.Sources

Representative appointed as director of the Japan Society for Biological Diagnostics.Sources

First feature on nematode cancer testing aired on an overseas program.Sources

NHK World Japan 'NEWS ROOM TOKYO'.Sources

Our company received its first in-depth coverage, broadcasting the research and development process.Sources

TV Tokyo affiliate 'Gaia no Yoake'.Sources

Newly added joint clinical research siteSources

Tokushima University Hematology, Toda Central General Hospital NephrologySources

Developer Hirotsu gave an invited lecture at the 60th Annual Meeting of the Japanese Society of Health CheckupsSources

Representative's book 'Cancer Screening is a Worm's Work' released by KōbunsōSources

Representative gave an invited presentation at the 16th Annual Meeting of the STS Forum Science and Technology in SocietySources

Establishment of U.S. subsidiary HIROTSU & CO., INC.Sources

Central Research Institute, Fukuoka Research Institute, Shikoku Analysis CenterSources

Renamed to Kashiwa R&D Center, Fukuoka R&D Center, Matsuyama R&D CenterSources

Opened HBS Tokyo Testing Center and HBS Matsuyama Testing CenterSources

Representative gave an invited lecture at the 2021 World Alliance Forum in San FranciscoSources

Newly added joint clinical research siteSources

Kurume University PediatricsSources

World's first nematode cancer testSources

Commercialized 'N-NOSE®', a primary cancer screening testSources

Numerous media reports on the commercialization of N-NOSESources

Public Interest Incorporated Association Platinum Concept NetworkSources

Our company received the 'Excellent Award' at the 8th Platinum AwardSources

Implemented third-party allotment capital increase for multiple companies (first round in 2020)Sources

Successfully developed the N-NOSE fully automatic analysis deviceSources

Moved headquarters to Kioi-cho, Chiyoda-ku, Tokyo due to business expansionSources

Launched the individual service 'Go To N-NOSE' for N-NOSE.Sources

Opened sample collection sites 'N-NOSE Station' in Tokyo and Fukuoka.Sources

Relocated and opened the Kashiwa R&D Center as the new Shonan R&D Center.Sources

The representative announced an invitation at the 4th International Health Screening Conference.Sources

Conducted a third-party allotment of additional capital with multiple companies (second round in 2020).Sources

[Newly added joint clinical research sites]Sources

University of Tsukuba Pediatrics, Kyoto Prefectural University of Medicine Pediatrics, Seiryoku Medical Center Pediatric Cancer Center, Komagome City Hospital Gastroenterology, Gifu University Oncology, Ageo Central General Hospital (2), University of Tokyo Gastric and Esophageal Surgery, Teikyo University Dermatology, Showa University Gastroenterology.Sources

Opened a sample collection site 'N-NOSE Station' in Osaka.Sources

First nationwide, the Fukuoka Prefecture branch of the Local Employees Mutual Aid Association adopted 'N-NOSE'.Sources

Signed a capital and business alliance agreement with Holipro Inc.Sources

Opened 'N-NOSE Station Satellite' sample collection sites nationwide.Sources

Conducted a third-party allotment of additional capital with multiple companies (first round in 2021).Sources

Launched the new service 'N-NOSE at home' that allows testing to be completed at home across all 47 prefectures.Sources

Conducted a third-party allotment of additional capital with multiple companies (second round in 2021).Sources

Signed a capital and business alliance agreement with Mitsui Sumitomo Insurance Co., Ltd. (Aioi).Sources

Opened a sample collection site 'N-NOSE Station' in Shinjuku.Sources

Our first corporate TV commercial began airing in the Kansai region.Sources

Announced that the world's first early pancreatic cancer test would be commercialized in 2022.Sources

This announcement was reported by over 300 news media outlets.Sources

Conducted a third-party allotment of additional capital with multiple companies (first round in 2022).Sources

Signed a capital and business partnership agreement with Sojitz Corporation.Sources

N-NOSE was certified by the "ME-BYO BRAND".Sources

Questions about nematode cancer testing technology were included in entrance exams for national universities and private high schools.Sources

Launched the "N-NOSE安心アフターサービス" (free) after-sales service.Sources

Introduced a new plan "Regular Inspection Course" that allows annual N-NOSE testing at a fixed number of times.Sources

Signed a capital and business partnership agreement with Tokyu Agency Co., Ltd.Sources

Hokkaido's Sarine Town became the first nationwide adopter of "N-NOSE" for a health promotion project and implemented it for residents.Sources

Representative delivered a keynote lecture at the 63rd Annual Meeting of the Japanese Society of Health Checkups.Sources

N-NOSE user count surpassed 250,000.Sources

First clinical research paper on N-NOSE targeting pets (dogs and cats) published by the company.Sources

Published in "Biochemistry and Biophysics Reports."Sources

Implemented an executive officer system.Sources

Participated in the Global Innovators Community of the World Economic Forum.Sources

Commercialized the first test "N-NOSE® plus pancreas."Sources

Signed a capital and business partnership agreement with Anicom General Insurance Co., Ltd.Sources

Launched the dog cancer test "N-NOSE® ワンちゃん" for pet owners.Sources

Signed a memorandum of understanding with the Global Health Equity Fund established by the WHO Foundation and others for overseas expansion of "N-NOSE®."Sources

Attended the World Economic Forum New Champion Annual Meeting 2023 (Summer Davos Conference).Sources

Listed "N-NOSE®" on Alibaba Group's cross-border e-commerce platform "Tmall Global."Sources

N-NOSE user count surpassed 500,000.Sources

Representative delivered a presentation at the public symposium 'STS Forum 2023'.Sources

Started accepting registrations for the cat cancer risk test 'N-NOSE Neko-chan'.Sources

Participated in 'UBS Disruptive Technology CEO Summit 2023'.Sources

Signed an official partnership agreement with Reco Blacklamas Tokyo.Sources

Implemented a third-party allotment of capital (first round in 2023).Sources

New director/CSO appointed.Sources

Number of corporate adopters of 'N-NOSE' surpassed 2,000 companies.Sources

Initiated a pilot study on unmanned sales and collection of 'N-NOSE'.Sources

Successfully developed a new cancer-type identification test for liver cancer.Sources

Appointed a global CFO to support overseas expansion.Sources

Launched new corporate service 'N-NOSE for Business'.Sources

Published a paper on the results of a large-scale clinical study of 'N-NOSE'.Sources

Implemented a third-party allotment of capital (first round in 2024).Sources

Selected as the 'Best Oral Abstract Presenter Award at EIOC 2024' at the Excellence in Oncology Care (EIOC) 2024 Conference.Sources

A peer-reviewed review on data demonstrating the real-world effectiveness of N-NOSE was published in the international biomedical journal 'Biomedicines'.Sources

Expanded the number of responsive cancer types from 15 to 23; launched 'N-NOSE® evolve'.Sources

Re-released 'N-NOSE plus Pancreas', specialized for pancreatic cancer, following positive reception.Sources

Suggested the effectiveness of 'N-NOSE' as a recurrence monitoring tool through a joint study with the University of Tokyo; the results were published in the international journal 'BMC Cancer'.Sources

Implemented a third-party allotment of capital (second round in 2024).Sources

Implemented a third-party allotment of capital.Sources

Proved the efficacy of N-NOSE in detecting blood cancersSources

The original paper was published in the international scientific journal 'Hematological Oncology'Sources

10 years since the invention of N-NOSESources

§07

News

20 ARTICLES

Recovery of Email Sending and Receiving Issues Due to Microsoft Inc. OutageSources

Due to a system outage at Microsoft Inc., our email system (Outlook) experienced sending and receiving issues. The service was restored on November 13, 2026, and email sending and receiving are now functioning normally. We are currently reviewing and responding to inquiries received during the outage. We sincerely apologize for any inconvenience and trouble caused.

[Announcement] The first part of the official YouTube program "Radio That Changes the World" featuring DJ KOO (TRF) has been releasedSources

HIROTSU BioScience Co., Ltd. released the first part of a conversation with DJ KOO of TRF as a guest on the official YouTube program "Radio That Changes the World – The Nematode Doctor Becomes President." The release took place on November 16, 2026 at 18:00. DJ KOO also participates in a pediatric cancer treatment support project, and this conversation will be streamed in two parts: the first and second segments.

Email Sending and Receiving Issues Due to Microsoft Inc. OutageSources

Due to a system outage at Microsoft Inc., our email system that uses Outlook is unavailable, preventing the receipt and sending of emails or causing significant delays. For urgent matters, please contact the sales representative directly, and other inquiries will be addressed sequentially after service restoration.

Clearson Shinjuku Players Release N-NOSE Experience VideoSources

HIROTSU Bioscience has released an interview video on its official YouTube channel and dedicated website, featuring Clearson Shinjuku players Shima Daijou, Nakayama Jintou, and Sawai Naoto sharing their experience of taking the "N-NOSE®" test at home. The players discuss the convenience of the test and how it provided peace of mind for themselves and their families.

N-NOSE tops the three key metrics in the major six-company surveySources

The first-line cancer screening test "N-NOSE®︎" achieved No.1 in the 2026 October market survey by the Japan Marketing Research Organization, ranking first among the major six companies in three categories: cumulative number of test takers, sales performance, and number of corporate welfare implementations. The company announced in July 2026 that it had surpassed one million cumulative samples and plans to continue promoting the test and improving its services. The survey results do not indicate the test’s effectiveness, efficacy, performance, or clinical superiority.

Interview with Representative Hirotsu Featured in MiraErrorSources

An interview article featuring Takayuki Hirotsu, CEO and Representative Director of HIROTSU BioScience Co., Ltd., was published in the executive interview media "MiraError." The piece introduces Hirotsu's career path, his passion for research and development, and the vision he aims to achieve through his business. The article was published on November 2, 2026.

HIROTSU BioScience Co., Ltd. Provides Special Sponsorship for the Pediatric Cancer Treatment Support Project "LIVE EMPOWER CHILDREN 2027"Sources

HIROTSU BioScience Co., Ltd. announced its special sponsorship of the "LIVE EMPOWER CHILDREN 2027 Project," a charity live and special program hosted by the nonprofit Empower Children. From November 2026 to January 2027, the company will visit four hospitals in the Kansai area to bring music and dance performances to children and their families. A special program, "LEC TV 2027," is scheduled to be broadcast on February 15, 2027.

Official YouTube Program "Radio That Changes the World" – Director Toshifumi Miyako's Second Half ReleaseSources

HIROTSU Bioscience Co., Ltd. has released the second half of the episode featuring Director Toshifumi Miyako on the official YouTube program "Radio That Changes the World." The second half includes a discussion on perspectives for selecting people, commonalities between team building and corporate management, and ways to encourage player growth.

Interview with CEO Hirotsu Featured in “Keido”Sources

On October 28, 2026, an interview with Takaki Hirotsu, Representative Director and CEO of HIROTSU Bio Science, was published in “Keido,” a media outlet featuring interviews with business leaders. The article covers topics including his transition from researcher to business leader, organizational management, research and development, and his views on overseas expansion.

HIROTSU Bio Science Participates in STS Forum 2026Sources

HIROTSU Bio Science, Inc. participated as a sponsor in STS Forum 2026, held from October 4 to 6, 2026, and was represented by Eric di Luccio, Senior Executive Officer and CTO. He shared his views on the frameworks needed to bring early cancer detection technologies into practical use in society and exchanged opinions with leaders in science, industry, and policymaking.

§08

Public records

GOV
National Tax Agency basic information4010401120144
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社HIROTSUバイオサイエンス
Trade name (kana)
ヒロツバイオサイエンス
Name in English
Corporation type
301
Address
〒102-0094 東京都千代田区紀尾井町4番1号
Postal code
1020094
Prefecture code
13
City code
101
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2020-10-13
Change date
2020-10-06
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
1748647
METI gBizINFO4010401120144
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
4010401120144
Trade name
株式会社HIROTSUバイオサイエンス
Trade name (kana)
ヒロツバイオサイエンス
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都千代田区紀尾井町4番1号
Postal code
1020094
Prefecture
東京都
Prefecture code
13
City or district
千代田区
City code
101
Street address
紀尾井町4番1号
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
Capital
Employees
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2020-10-13
Key information
4010401120144
§09

Sources & updates

SOURCES
↑